What is Immunome's G&A?

Immunome (IMNM) reported G&A of $12.95M in Q1 2026.

How has Immunome's G&A changed year-over-year?

Immunome's G&A increased by 21.1% year-over-year, from $10.69M to $12.95M.

What is the long-term trend for Immunome's G&A?

Over 4 years (2021 to 2025), Immunome's G&A has grown at a 40.9% compound annual growth rate (CAGR), from $11.09M to $43.77M.

Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.

Immunome IMNM G&A

G&A at other companies

Arcus BiosciencesRCUS

$29M+3.6%

SELLAS Life Sciences Group, Inc.SLS

$4.12M+44.3%

IDEAYA Biosciences, Inc.IDYA

$19.38M+43.5%

Summit TherapeuticsSMMT

$62.59M+302%

Immunovant, Inc.IMVT

$17.27M-14.4%

Nektar TherapeuticsNKTR

$13.44M-44.8%

Segments

By segment

See full

Single Reportable-$8.65M-17.3%

Other financials

Income statement

See full

Revenue--100%

Operating income-$59.3M-32.9%

Net income-$53.8M-29.3%

EPS (diluted)-$0.48+7.7%

Balance sheet

See full

Cash & equivalents$582.7M+126%

Total debt$3.7M-22.6%

Total equity$588.7M+91.7%

Total assets$619.8M+80.9%

Cash flow

See full

Operating cash flow-$58.6M-10.5%

CapEx$3.0M-18.1%

Free cash flow-$61.6M-8.7%

Valuation

See full

Market cap$2.19B+323%

Enterprise value$1.61B+470%

P/S545.2×+498×

Profitability

See full

Operating margin-5,947.9%-12,002pp

Net margin-5,593.8%-11,284pp

FCF margin-5,118.9%-8,601pp

Returns & leverage

See full

Return on equity-50.1%-10.8pp

Debt / equity0×0.0×

Current ratio21.7×+11.2×

Where this comes from

Reported directly by Immunome in its filing.

Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.

The official record: Immunome’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Immunome's g&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Immunome's G&A?: Immunome (IMNM) reported G&A of $12.95M in Q1 2026.
How has Immunome's G&A changed year-over-year?: Immunome's G&A increased by 21.1% year-over-year, from $10.69M to $12.95M.
What is the long-term trend for Immunome's G&A?: Over 4 years (2021 to 2025), Immunome's G&A has grown at a 40.9% compound annual growth rate (CAGR), from $11.09M to $43.77M.
What does G&A mean?: Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.